Free Access
Med Sci (Paris)
Volume 34, Number 3, Mars 2018
Page(s) 267 - 274
Section Forum
Published online 16 March 2018
  1. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7 : 24. [CrossRef] [PubMed] [Google Scholar]
  2. Fischer K, Steen Carlsson K, Petrini P, et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122 : 1129-36. [Google Scholar]
  3. Murphy SL, High KA. Gene therapy for haemophilia. Br J Haematol 2008; 140 : 479-87. [CrossRef] [PubMed] [Google Scholar]
  4. Lu DR1, Zhou JM, Zheng B, et al. Stage I clinical trial of gene therapy for hemophilia B. Sci China B 1993; 36 : 1342-51. [PubMed] [Google Scholar]
  5. Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med 2017; 377 : 2519-30. [Google Scholar]
  6. George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med 2017; 377 : 2215-27. [Google Scholar]
  7. Van den Berg. A cure for hemophilia within reach. N Engl J Med 2017; 377 : 2592-3. [Google Scholar]
  8. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. Communiqué de la FDA, 19 décembre 2017, voir : [Google Scholar]
  9. Jordan B. Immunothérapie « CAR-T » : une autorisation qui fait date. Med Sci (Paris) 2017; 33 : 1003-6. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.